IMUGENE LIMITED — Board/Management Information 2019

Jan 6, 2019

ASX Announcement

==> picture [116 x 42] intentionally omitted <==

Imugene appoints distinguished scientist, Dr Michael Caligiuri of City of Hope to Scientific Advisory Board

---

• President of City of Hope National Medical Center and holds the Deana and Steve Campbell Physician-in-Chief.

• Elected President of the American Association for Cancer Research (AACR) in 2017, the world’s largest cancer research organization.

Sydney, Australia, 07 January 2019: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announced the appointment of Professor Michael Caligiuri, President of the City of Hope National Medical Center in Los Angeles, to its Scientific Advisory Board (SAB).

Dr. Caligiuri is a world renowned cancer researcher and physician whose clinical work has focused on leukemia and lymphoma.

Since 1990, over 100 students have trained in the Caligiuri laboratory and have received over 200 awards for their research. Dr. Caligiuri has designed and conducted many clinical studies for over 1500 leukemia and lymphoma patients.

Imugene’s M.D. & CEO, Ms Leslie Chong said “It is a great honor for Imugene to have such a distinguished scientist join our team. Dr Caligiuri has devoted his career and his scientific discoveries for the benefit of millions of patients whose lives have been impacted by cancer. He is a prodigious researcher with over 380 published works to his name, and I am sure his contribution to Imugene will be profound.”

Prior to his appointment at City of Hope in February of 2018, Dr. Caligiuri was The CEO of The Ohio State University (OSU) James Cancer Hospital (2008-2017) and Director of OSU’s Comprehensive Cancer Center (2003-2017); he had been the Director of OSU’s Division of Hematology-Oncology from 2000 through 2008.

Dr. Caligiuri is an elected member of the American Association for Clinical Investigation and the American Association of Physicians, and he is an elected Fellow in the American Association for the Advancement

IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM info@imugene.com

of Science (AAAS). From 2009-2011, he served as president of the Association for American Cancer Institutes (AACI). From 2014-2017 he served as the president of the Society of Natural Immunity.

In 2017 he was elected president of the American Association for Cancer Research (AACR), the world’s largest cancer research organization.

Dr. Caligiuri has served on the National Cancer Institute (NCI) Board of Scientific Counselors and Board of Scientific Advisors; He was chairman of the Institute of Medicine’s National Cancer Policy Forum from 2014-2016. He is a chairman and/or member of 10 cancer center advisory boards across the country.

In 2010, Dr. Caligiuri was one of four individuals in the country to receive a MERIT award from the National Cancer Institute for his work on immunity and cancer, and in 2016 he received an Outstanding Investigator Award from the National Cancer Institute. In 2018, Dr. Caligiuri was elected a Fellow of the AACR Academy.

Dr Caligiuri said “I am pleased to join the Scientific Advisory Board of Imugene. I am familiar with their B- cell peptide vaccines from my time at Ohio State University, and look forward to being part of the team to advance the technology through the clinic.”

For further information please contact:

Leslie Chong Managing Director and Chief Executive Officer T: +61 458 040 433 E: Leslie.Chong@Imugene.com

Follow us on Twitter @TeamImugene Like us on Facebook @Imugene Connect with us on LinkedIn @Imugene Limited

2

IMUGENE LIMITED ACN 009 179 551

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technology seeks to harness the body’s immune system to generate antibodies against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody therapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become a foundation treatment for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

3

IMUGENE LIMITED ACN 009 179 551